Literature DB >> 28303892

How good are we at predicting the fate of someone with acute myeloid leukaemia?

E Estey1, R P Gale2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28303892     DOI： 10.1038/leu.2017.56

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  29 in total

1.  Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.

Authors:  X Chen; L F Newell; H Xie; R B Walter; J M Pagel; V K Sandhu; P S Becker; P C Hendrie; J L Abkowitz; F R Appelbaum; E H Estey
Journal:  Leukemia       Date:  2015-02-04       Impact factor: 11.528

2.  Acute myeloid leukemia therapy and the chosen people.

Authors:  E Estey; R P Gale
Journal:  Leukemia       Date:  2016-11-11       Impact factor: 11.528

3.  Tolerating Uncertainty - The Next Medical Revolution?

Authors:  Arabella L Simpkin; Richard M Schwartzstein
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

Review 4.  Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide.

Authors:  Maarten J G Leening; Moniek M Vedder; Jacqueline C M Witteman; Michael J Pencina; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2014-01-21       Impact factor: 25.391

5.  Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.

Authors:  T Büchner; U O Krug; R Peter Gale; A Heinecke; M C Sauerland; C Haferlach; S Schnittger; T Haferlach; C Müller-Tidow; M Stelljes; R M Mesters; H L Serve; J Braess; K Spiekermann; P Staib; A Grüneisen; A Reichle; L Balleisen; H Eimermacher; A Giagounidis; H Rasche; E Lengfelder; D Görlich; A Faldum; W Köpcke; R Hehlmann; B J Wörmann; W E Berdel; W Hiddemann
Journal:  Leukemia       Date:  2016-03-11       Impact factor: 11.528

6.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

Authors:  Utz Krug; Christoph Röllig; Anja Koschmieder; Achim Heinecke; Maria Cristina Sauerland; Markus Schaich; Christian Thiede; Michael Kramer; Jan Braess; Karsten Spiekermann; Torsten Haferlach; Claudia Haferlach; Steffen Koschmieder; Christian Rohde; Hubert Serve; Bernhard Wörmann; Wolfgang Hiddemann; Gerhard Ehninger; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

7.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Authors:  Stephen H Petersdorf; Kenneth J Kopecky; Marilyn Slovak; Cheryl Willman; Thomas Nevill; Joseph Brandwein; Richard A Larson; Harry P Erba; Patrick J Stiff; Robert K Stuart; Roland B Walter; Martin S Tallman; Leif Stenke; Frederick R Appelbaum
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

8.  Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.

Authors:  R B Walter; M Othus; E M Paietta; J Racevskis; H F Fernandez; J-W Lee; Z Sun; M S Tallman; J Patel; M Gönen; O Abdel-Wahab; R L Levine; E H Estey
Journal:  Leukemia       Date:  2015-03-16       Impact factor: 11.528

9.  Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.

Authors:  M Othus; B L Wood; D L Stirewalt; E H Estey; S H Petersdorf; F R Appelbaum; H P Erba; R B Walter
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

10.  Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.

Authors:  R F Schlenk; P Frech; D Weber; P Brossart; H-A Horst; D Kraemer; G Held; M Ringhoffer; A Burchardt; G Kobbe; K Götze; D Nachbaur; T Fischer; M Lübbert; H R Salih; H Salwender; G Wulf; E Koller; M Wattad; W Fiedler; S Kremers; H Kirchen; B Hertenstein; P Paschka; V I Gaidzik; V Teleanu; M Heuser; F Thol; K Döhner; J Krauter; A Ganser; H Döhner
Journal:  Leukemia       Date:  2017-01-18       Impact factor: 11.528
View more
  5 in total

Review 1.  Cytotoxic therapy in acute myeloid leukemia: not quite dead yet.

Authors:  Laura C Michaelis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.

Authors:  Roni Shouval; Joshua A Fein; Aniela Shouval; Ivetta Danylesko; Noga Shem-Tov; Maya Zlotnik; Ronit Yerushalmi; Avichai Shimoni; Arnon Nagler
Journal:  Blood Adv       Date:  2019-06-25

3.  Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation.

Authors:  Megan Othus; Robert Peter Gale; Christopher S Hourigan; Roland B Walter
Journal:  Bone Marrow Transplant       Date:  2019-10-30       Impact factor: 5.483

4.  Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models.

Authors:  Fang Hu; Yun Wang; Wei-da Wang; Robert Peter Gale; Bing-Yi Wu; Yang Liang
Journal:  Leukemia       Date:  2021-08-07       Impact factor: 12.883

5.  HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy.

Authors:  Vincent Alcazer; Paola Bonaventura; Laurie Tonon; Emilie Michel; Virginie Mutez; Clémentine Fabres; Nicolas Chuvin; Rasha Boulos; Yann Estornes; Véronique Maguer-Satta; Kevin Geistlich; Alain Viari; Klaus H Metzeler; Wolfgang Hiddemann; Aarif M N Batch; Tobias Herold; Christophe Caux; Stéphane Depil
Journal:  Am J Hematol       Date:  2022-07-12       Impact factor: 13.265
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.